Cerebrospinal fluid, cell lysates and tissue homogenates open new avenues for biomarker discovery in oncology and neurology SOUTH SAN FRANCISCO, Calif. , Sept. 24, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), today announced that the SomaScan ® 11K Platform now includes protein
Researchers used Standard BioTools’ high-content SomaScan® Platform and SomaSignal™ tests for MASH/NASH to identify 69 blood biomarkers that correlate with clinical measures of liver disease SOUTH SAN FRANCISCO, Calif. , Sept. 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif. , Aug. 26, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), today announced its President and Chief Executive Officer, Michael Egholm , PhD, will present at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference taking place Wednesday September
SOUTH SAN FRANCISCO, Calif. , Aug. 06, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), today announced that its management team will participate in the following investor conferences in the month of August: Canaccord Genuity 44 th Annual Growth Conference on August 13 th , 2024
Alex Kim , Chief Operating Officer and Standard BioTools Co-Founder, to Serve as interim Chief Financial Officer Following Departure of Jeffrey Black on August 31, 2024 Industry Veteran Sean Mackay Named Chief Business Officer SOUTH SAN FRANCISCO, Calif.
Delivered revenue of $37.2 million Accelerated merger synergies with $80 million expected to be operationalized in 2024 Revised FY2024 revenue guidance; on-track to achieve anticipated break-even adjusted EBITDA for full-year 2026 Current balance sheet of $396 million cash, cash equivalents,
SOUTH SAN FRANCISCO, Calif. , July 17, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report second quarter 2024 financial results on Wednesday, July 31, 2024, after the close of the market.
SOUTH SAN FRANCISCO, Calif and SALT LAKE CITY , May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that it has purchased the LSA XT system from Carterra ® , a leading provider of high-throughput large and small molecule screening and characterization solutions.
SOUTH SAN FRANCISCO, Calif. , May 22, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools”) (Nasdaq:LAB) today announced that its management team will participate in the following investor conferences in the month of June: Jefferies Global Healthcare Conference on June 5 th & 6 th
SOUTH SAN FRANCISCO, Calif. , May 20, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools”) (Nasdaq:LAB) today announced that the Human Capital Committee of its Board of Directors, which is composed entirely of independent directors, granted an equity award effective as of May 20,
